AI Article Synopsis

  • Vaccination is being explored as a potential alternative to chemical treatments for sarcoptic mange; however, effective vaccines have not been developed yet.
  • Researchers in this study identified an immunodominant antigen, Ssλ15, from the Sarcoptes scabiei parasite and tested it as a vaccine candidate in rabbits alongside another antigen.
  • The trial indicated that while the vaccination produced high levels of specific antibodies, it ultimately did not confer clinical protection against the parasite and resulted in more severe lesions, suggesting an adverse immune response rather than effective protection.

Article Abstract

Background: Vaccination is an attractive ecological alternative to the use of acaricides for parasite control. However, effective anti-parasite vaccines against sarcoptic mange have not yet been developed. The purpose of this study was first to identify Sarcoptes scabiei immunodominant antigens and second to evaluate them as vaccine candidates in a rabbit/S. scabiei var. cuniculi model.

Methods: The S. scabiei Ssλ15 immunodominant antigen was selected by immunoscreening of a S. scabiei var. hominis cDNA. The full-length cDNA was sequenced and cloned into the pGEX vector and the recombinant protein expressed in BL21 (DE3) cells and purified. A vaccination trial was performed consisting of a test group (n = 8) immunised with recAgs (a mix of two recombinant antigens, Ssλ15 and the previously described Ssλ20∆B3) and a control group (n = 8) immunised with PBS. All analyses were performed with R Statistical Environment with α set at 0.050.

Results: The full-length open reading frame of the 1,821 nt cloned cDNA encodes a 64 kDa polypeptide, the sequence of which had 96 % identity with a hypothetical protein of S. scabiei. Ssλ15 was localised by immunostaining of skin sections in the tegument surrounding the mouthparts and the coxa in the legs of mites. Rabbit immunisation with recAgs induced high levels of specific IgG (P < 0.010) and increased levels of total IgEs. However, no significant clinical protection against S. scabiei challenge was detected. Unexpectedly, the group immunised with the recAgs mix had significantly higher lesion scores (P = 0.050) although lower mean mite densities than those observed in the control group. These results might indicate that the lesions in the recAgs group were due not only to the mites density but also to an exacerbated immunological response after challenge, which is in agreement with the specific high levels of pro-inflammatory cytokines (IL-1 and TNFα) detected after challenge in this group.

Conclusions: The selected antigens delivered as recombinant proteins had no clinical protective efficacy against S. scabiei infestation although immunisation reduced mite density. However, these results pave the way for future studies on alternative production systems, adjuvants, delivery methods and combinations of antigens in order to manage stimulation of clinical protective immune responses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977775PMC
http://dx.doi.org/10.1186/s13071-016-1717-9DOI Listing

Publication Analysis

Top Keywords

immunodominant antigens
8
sarcoptes scabiei
8
induced high
8
high levels
8
scabiei var
8
scabiei ssλ15
8
group n = 8
8
n = 8 immunised
8
scabiei
6
vaccination rabbits
4

Similar Publications

Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii.

Sci Rep

January 2025

Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Acinetobacter baumannii, an opportunistic bacterium prevalent in various environment, is a significant cause of nosocomial infections in ICUs. As the causative agent of pneumonia, septicemia, and meningitis, A. baumannii typically exhibits multidrug resistance and is associated with poor prognosis, thus led to a challenge for researchers in developing new treatment and prevention methods.

View Article and Find Full Text PDF

Influenza remains a persistent global health challenge, largely due to the virus' continuous antigenic drift and occasional shift, which impede the development of a universal vaccine. To address this, the identification of broadly neutralizing antibodies and their epitopes is crucial. Nanobodies, with their unique characteristics and binding capacity, offer a promising avenue to identify such epitopes.

View Article and Find Full Text PDF

Although peptide vaccines offer a novel venue for cancer immunotherapy, clinical success has been rather limited. Cell-penetrating peptides, due to their ability to translocate through the cell membrane, could be conjugated to the peptide vaccine to2 enhance therapeutic efficiency. The S4 transduction domain of the shaker-potassium channel was conjugated to mammaglobin-A (MamA) immunodominant epitope (MamA2.

View Article and Find Full Text PDF

Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later.

J Infect

December 2024

ISGlobal, Barcelona, Spain; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Barcelona, Spain. Electronic address:

Objectives: We aimed to evaluate the adaptive immune responses' cross-recognition of the hypermutated SARS-CoV-2 BA.2.86 variant and identify the determinants influencing this recognition.

View Article and Find Full Text PDF

Immunodominant Molecules for the Immunodiagnosis of Strongyloides stercoralis Infection.

Diagn Microbiol Infect Dis

December 2024

Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal da Bahia, Brazil. Electronic address:

Article Synopsis
  • The study focused on identifying key immune molecules for diagnosing S. stercoralis infections using serum samples tested with specific antigens (AgS and AgM).
  • Results from IgG-ELISA showed decent sensitivity (82.3 to 85.3%) and varying specificity (60.0 to 93.3%), but some cross-reactivity with other helminth infections was noted.
  • A specific 140 kDa protein from AgS demonstrated perfect sensitivity and specificity without cross-reactivity, indicating its potential for creating reliable immunodiagnostic tests for strongyloidiasis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!